Under the terms of this agreement, Kaketsuken will provide Baxter with access to Kaketsuken's intellectual property rights concerning the recombinant protein. Baxter has an exclusive license to the recombinant ADAMTS13 intellectual property rights worldwide, except for Japan where Baxter has a co-exclusive license to commercialize recombinant ADAMTS13 with Kaketsuken. In addition to an upfront payment upon signing the agreement, Baxter will pay Kaketsuken milestone payments upon Investigational New Drug (IND) filing, initiation of Phase II and Phase III trials, Biologics License Application (BLA) filings and US Food and Drug Administration approval of recombinant ADAMTS13.
The inclusion of ADAMTS13 in Baxter's pre-clinical portfolio fits into the company's platform of specialty pharmaceuticals. Baxter has pioneered protein therapies developed from the separation and purification of important blood components and recombinant technologies, applying its knowledge and resources to become a leader in blood-related disorders such as hemophilia and other immune deficiencies. Baxter is recognized as a global leader in hemophilia therapies with a growing portfolio of innovative therapies and technologies, developed through strategic collaborations and internal research and development.
TTP is a thrombotic disorder that is caused by the formation of
platelet- rich thrombi in blood vessels throughout the body. Hereditary
TTP, also known as Upshaw Schulman syndrome, is caused by detrimental
mutations of the ADAMTS13 gene, resulting in severe ADAMTS13 deficiency,
whereas acquired TTP is often due to auto-antibodies directed against
ADAMTS13. Characterized by bruising, anemia, fever, n
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved